+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Prostate Cancer Treatment Market by Drug Type and Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2019-2026

  • ID: 5021816
  • Report
  • January 2020
  • Region: Global
  • 188 pages
  • Allied Analytics LLP
1 of 5

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Astellas Pharma Inc.
  • AstraZeneca plc
  • Bayer AG
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline Plc
  • Ipsen Pharma
  • MORE
The global prostate cancer treatment market was valued at $6,887 million in 2018, and is projected to reach $9,904 million by 2026, registering a CAGR of 4.6% from 2019 to 2026. Prostate cancer is a type of cancer that develops in the male reproductive system. It is asymptomatic, and grow slowly at its earliest stages. Furthermore, it is the second most common cancer in male after skin cancer. In case of treatment, the initial stage of prostate cancer are treated by radiation therapy, and for the last stages, where tumor has spread beyond the prostate gland, drug therapies are recommended. The drug therapies include chemotherapy, biological therapy, and hormone therapy. Xtandi and Zytiga are the major therapeutic drugs that are used for the treatment of prostate cancer.

Significant increase in prevalence of prostate cancer, rise in geriatric population, surge in awareness among people regarding the treatment of prostate cancer, increase in demand for prostate cancer treatment products, and rise in uptake of hormonal agents in non-metastatic castration resistant (nmCRPC) & metastatic hormone nave (mHNPC) prostate cancer settings are the key factors that fuel the growth of the prostate cancer treatment market. Moreover, availability of new prostate cancer treatments, strong emerging pipeline drugs, improved R&D investment by drug innovators, enhanced diagnosis & incidence rates in developed economies, increase in generic products, and rise in pharmaceutical industries & diagnostic centers across the globe contribute toward the growth of the market. However, prolonged treatment durations and poor demand for prostate cancer treatment drugs in underdeveloped countries are expected to hinder the growth of the market.

The prostate cancer treatment market is segmented on the basis of drug type, distribution channel, and region. By drug type, the market is categorized into chemotherapy, biological therapy, hormone therapy, and others. Depending on the distribution channel, the market is classified into hospitals pharmacies, drug stores & retail pharmacies, and online pharmacies. On the basis of region, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

KEY BENEFITS FOR STAKEHOLDERS
  • The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
  • It offers a quantitative analysis from 2018 to 2026, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities.
  • A comprehensive analysis of all the geographical regions is provided to determine the existing opportunities.
  • The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.
KEY MARKET SEGMENTS

By Drug Type
  • Chemotherapy
  • Biological Therapy
  • Hormone Therapy
  • Others
By Distribution Channel
  • Hospitals Pharmacies
  • Drug Stores & Retail Pharmacies
  • Online Pharmacies
By Region
  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • Australia
  • India
  • South Korea
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA
LIST OF KEY PLAYERS PROFILED IN THE REPORT
  • Astellas Pharma Inc.
  • AstraZeneca plc
  • Bayer AG
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche AG
  • Ferring Pharmaceuticals Inc.
  • GlaxoSmithKline Plc
  • Ipsen Pharma
  • Johnson & Johnson
  • Takeda Pharmaceutical Company Ltd
LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request.)
  • Tolmar Inc.
  • Indevus Pharmaceuticals
  • Sanofi S.A.
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Astellas Pharma Inc.
  • AstraZeneca plc
  • Bayer AG
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline Plc
  • Ipsen Pharma
  • MORE
Chapter 1: Introduction
1.1. Report Description
1.2. Key Benefits For Stakeholders
1.3. Key Market Segments
1.3.1. List of Key Players Profiled In The Report
1.4. Research Methodology
1.4.1. Secondary Research
1.4.2. Primary Research
1.4.3. Analyst Tools And Models

Chapter 2: Executive Summary
2.1. Key Findings of The Study
2.2. Cxo Perspective

Chapter 3: Market Overview
3.1. Market Definition And Scope
3.2. Key Findings
3.2.1. Top Investment Pockets
3.2.2. Market Player Positioning, 2018
3.3. Porter's Five Force Analysis
3.4. Market Dynamics
3.4.1. Drivers
3.4.1.1. Increase In Prevalence of Prostate Cancer
3.4.1.2. Rise In In Geriatric Population
3.4.1.3. Increase In Government Expenditure On Healthcare
3.4.2. Restraint
3.4.2.1. Adverse Effects Associated With The Use Prostate Cancer Treatment Drugs
3.4.3. Opportunities
3.4.3.1. Growth Opportunities In Emerging Markets
3.4.4. Impact Analysis

Chapter 4: Prostate Cancer Treatment Market, By Drug Type
4.1. Overview
4.1.1. Market Size And Forecast
4.2. Hormone Therapy
4.2.1. Key Market Trends, Growth Factors, And Opportunities
4.2.2. Market Size And Forecast, By Region
4.2.3. Market Analysis, By Country
4.3. Biological Therapy
4.3.1. Key Market Trends, Growth Factors, And Opportunities
4.3.2. Market Size And Forecast
4.3.3. Market Analysis, By Country
4.4. Chemotherapy
4.4.1. Key Market Trends, Growth Factors, And Opportunities
4.4.2. Market Size And Forecast
4.4.3. Market Analysis, By Country
4.5. Others
4.5.1. Key Market Trends, Growth Factors, And Opportunities
4.5.2. Market Size And Forecast
4.5.3. Market Analysis, By Country

Chapter 5: Prostate Cancer Treatment Market, By Distribution Channel
5.1. Overview
5.1.1. Market Size And Forecast
5.2. Hospital Pharmacy
5.2.1. Market Size And Forecast
5.2.2. Market Analysis, By Country
5.3. Drug Stores & Retail Pharmacy
5.3.1. Market Size And Forecast
5.3.2. Market Analysis, By Country
5.4. Online Pharmacy
5.4.1. Market Size And Forecast
5.4.2. Market Analysis, By Country

Chapter 6: Prostate Cancer Treatment Market, By Region
6.1. Overview
6.1.1. Market Size And Forecast
6.2. North America
6.2.1. Key Market Trends, Growth Factors, And Opportunities
6.2.2. Market Size And Forecast, By Country
6.2.2.1. U.S.
6.2.2.1.1. U.S. Prostate Cancer Treatment Market, By Drug Type
6.2.2.1.2. U.S. Prostate Cancer Treatment Market, By Distribution Channel
6.2.2.2. Canada
6.2.2.2.1. Canada Prostate Cancer Treatment Market, By Drug Type
6.2.2.2.2. Canada Prostate Cancer Treatment Market, By Distribution Channel
6.2.2.3. Mexico
6.2.2.3.1. Mexico Prostate Cancer Treatment Market, By Drug Type
6.2.2.3.2. Mexico Prostate Cancer Treatment Market, By Distribution Channel
6.2.3. North America Market Size And Forecast, By Drug Type
6.2.4. North America Market Size And Forecast, By Distribution Channel
6.3. Europe
6.3.1. Key Market Trends, Growth Factors, And Opportunities
6.3.2. Market Size And Forecast, By Country
6.3.2.1. Germany
6.3.2.1.1. Germany Prostate Cancer Treatment Market, By Drug Type
6.3.2.1.2. Germany Prostate Cancer Treatment Market, By Distribution Channel
6.3.2.2. France
6.3.2.2.1. France Prostate Cancer Treatment Market, By Drug Type
6.3.2.2.2. France Prostate Cancer Treatment Market, By Distribution Channel
6.3.2.3. UK
6.3.2.3.1. UK Prostate Cancer Treatment Market, By Drug Type
6.3.2.3.2. UK Prostate Cancer Treatment Market, By Distribution Channel
6.3.2.4. Italy
6.3.2.4.1. Italy Prostate Cancer Treatment Market, By Drug Type
6.3.2.4.2. Italy Prostate Cancer Treatment Market, By Distribution Channel
6.3.2.5. Spain
6.3.2.5.1. Spain Prostate Cancer Treatment Market, By Drug Type
6.3.2.5.2. Spain Prostate Cancer Treatment Market, By Distribution Channel
6.3.2.6. Rest of Europe
6.3.2.6.1. Rest of Europe Prostate Cancer Treatment Market, By Drug Type
6.3.2.6.2. Rest of Europe Prostate Cancer Treatment Market, By Distribution Channel
6.3.3. Europe Market Size And Forecast, By Drug Type
6.3.4. Europe Market Size And Forecast, By Distribution Channel
6.4. Asia-Pacific
6.4.1. Key Market Trends, Growth Factors, And Opportunities
6.4.2. Market Size And Forecast, By Country
6.4.2.1. Japan
6.4.2.1.1. Japan Prostate Cancer Treatment Market, By Drug Type
6.4.2.1.2. Japan Prostate Cancer Treatment Market, By Distribution Channel
6.4.2.2. China
6.4.2.2.1. China Prostate Cancer Treatment Market, By Drug Type
6.4.2.2.2. China Prostate Cancer Treatment Market, By Distribution Channel
6.4.2.3. Australia
6.4.2.3.1. Australia Prostate Cancer Treatment Market, By Drug Type
6.4.2.3.2. Australia Prostate Cancer Treatment Market, By Distribution Channel
6.4.2.4. India
6.4.2.4.1. India Prostate Cancer Treatment Market, By Drug Type
6.4.2.4.2. India Prostate Cancer Treatment Market, By Distribution Channel
6.4.2.5. South Korea
6.4.2.5.1. South Korea Prostate Cancer Treatment Market, By Drug Type
6.4.2.5.2. South Korea Prostate Cancer Treatment Market, By Distribution Channel
6.4.2.6. Rest of Asia-Pacific
6.4.2.6.1. Rest of Asia-Pacific Prostate Cancer Treatment Market, By Drug Type
6.4.2.6.2. Rest of Asia-Pacific Prostate Cancer Treatment Market, By Distribution Channel
6.4.3. Asia-Pacific Market Size And Forecast, By Drug Type
6.4.4. Asia-Pacific Market Size And Forecast, By Distribution Channel
6.5. LAMEA
6.5.1. Key Market Trends, Growth Factors, And Opportunities
6.5.2. Market Size And Forecast, By Country
6.5.2.1. Brazil
6.5.2.1.1. Brazil Prostate Cancer Treatment Market, By Drug Type
6.5.2.1.2. Brazil Prostate Cancer Treatment Market, By Distribution Channel
6.5.2.2. Saudi Arabia
6.5.2.2.1. Saudi Arabia Prostate Cancer Treatment Market, By Drug Type
6.5.2.2.2. Saudi Arabia Prostate Cancer Treatment Market, By Distribution Channel
6.5.2.3. South Africa
6.5.2.3.1. South Africa Prostate Cancer Treatment Market, By Drug Type
6.5.2.3.2. South Africa Prostate Cancer Treatment Market, By Distribution Channel
6.5.2.4. Rest of LAMEA
6.5.2.4.1. Rest of LAMEA Prostate Cancer Treatment Market, By Drug Type
6.5.2.4.2. Rest of LAMEA Prostate Cancer Treatment Market, By Distribution Channel
6.5.3. LAMEA Market Size And Forecast, By Drug Type
6.5.4. LAMEA Market Size And Forecast, By Distribution Channel

Chapter 7: Company Profiles
7.1. Astellas Pharma Inc.
7.1.1. Company Overview
7.1.2. Company Snapshot
7.1.3. Operating Business Segments
7.1.4. Product Portfolio
7.1.5. Business Performance
7.2. Astrazeneca Plc
7.2.1. Company Overview
7.2.2. Company Snapshot
7.2.3. Operating Business Segments
7.2.4. Product Portfolio
7.2.5. Business Performance
7.3. Bayer Ag.
7.3.1. Company Overview
7.3.2. Operating Business Segments
7.3.3. Product Portfolio
7.3.4. Business Performance
7.3.5. Key Strategic Moves And Developments
7.4. Bristol-Myers Squibb Company
7.4.1. Company Overview
7.4.2. Company Snapshot
7.4.3. Operating Business Segments
7.4.4. Product Portfolio
7.4.5. Business Performance
7.5. F. Hoffmann-La Roche Ag
7.5.1. Company Overview
7.5.2. Company Snapshot
7.5.3. Operating Business Segments
7.5.4. Product Portfolio
7.5.5. Business Performance
7.6. Ferring Pharmaceuticals Inc.
7.6.1. Company Overview
7.6.2. Company Snapshot
7.6.3. Operating Business Segments
7.6.4. Product Portfolio
7.6.5. Business Performance
7.7. Glaxosmithkline Plc.
7.7.1. Company Overview
7.7.2. Operating Business Segments
7.7.3. Product Portfolio
7.7.4. Business Performance
7.8. Ipsen Pharma
7.8.1. Company Overview
7.8.2. Company Snapshot
7.8.3. Operating Business Segments
7.8.4. Product Portfolio
7.8.5. Business Performance
7.9. Johnson & Johnson
7.9.1. Company Overview
7.9.2. Company Snapshot
7.9.3. Operating Business Segments
7.9.4. Product Portfolio
7.9.5. Business Performance
7.9.6. Key Strategic Moves And Developments: Global
7.10. Takeda Pharmaceutical Company Ltd
7.10.1. Company Overview
7.10.2. Company Snapshot
7.10.3. Operating Business Segments
7.10.4. Product Portfolio
7.10.5. Business Performance
Note: Product cover images may vary from those shown
3 of 5

FEATURED COMPANIES

  • Astellas Pharma Inc.
  • AstraZeneca plc
  • Bayer AG
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline Plc
  • Ipsen Pharma
  • MORE
According to the report, titled, 'Prostate Cancer Treatment Market by Drug Type and Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2019-2026,' the global prostate cancer treatment market size was valued at $6,887 million in 2018, and is projected to reach $9,904 million by 2026, growing at a CAGR of 4.6% from 2019 to 2026.

Prostate cancer is a type of cancer that develops into male reproductive system. Prostate cancer begins when normal cells in the prostate gland start multiplying uncontrollably. It is more prevalent in geriatric men over the age of 65 years. Risk factors for development of prostate cancer are family history, race, and old age. It can be treated by radiation therapy, surgery, chemotherapy, biological therapy, and hormone therapy. The treatment for prostate cancer can be decided on the basis of the stage of cancer. The healthcare professionals such as radiation oncologists and urologists treat prostate cancer.

The prostate cancer treatment market is expected to experience significant growth during the forecast period, owing to rise in prevalence of prostate cancer, increase in demand for prostate cancer treatment products, strong emerging pipeline drugs, availability of new prostate cancer treatments, and an increase in awareness among people regarding the treatments of prostate cancer. In addition, surge in uptake of hormonal agents in non-metastatic castration resistant (nmCRPC) & metastatic hormone nave (mHNPC) prostate cancer settings, rise in geriatric population, improved R&D investment by drug innovators, rise in generic products, increase in healthcare expenditure in the developed and developing regions, growth in pharmaceutical industries & diagnostic centers across the globe are expected to further drive the growth of the global prostate cancer treatment market. However, prolonged treatment durations and poor demand for prostate cancer treatment drugs in underdeveloped countries are expected to restrain the growth of the market.

Based on drug type, the prostate cancer treatment market is categorized into chemotherapy, biological therapy, and hormone therapy. Presently, hormone therapy segment dominates the global market, and is anticipated to continue this trend during the forecast period. The key factors that drive the prostate cancer treatment market growth include rise in prevalence of prostate cancer coupled with growing public awareness regarding the treatments of prostate cancer, surge in demand for hormone therapy drugs, availability of generic drugs, and an increase in number of pharmaceutical companies across the globe.

Based on the distribution channel, the market is classified into hospital pharmacies, drug stores & retail pharmacies, and online pharmacies. Currently, the hospital pharmacies segment accounted for the majority of market share, owing to the rise in the number of hospitalized prostate cancer patients, convenience offered by them, and strong presence of hospital pharmacies across the globe. The online pharmacies is the fastest growing segment, at a CAGR of 6.4% from 2019 to 2026, owing to increase in preference for online purchasing of drugs over the traditional methods, increase in awareness regarding online pharmacies, and rise in number of internet users.

Key Findings of the Study
Based on drug type, the hormone therapy segment held more than one-third share in the global prostate cancer treatment market in 2018.
Based on the distribution channel, the hospital pharmacies segment held more than half share in the global market in 2018.
Based on region, Asia-Pacific is expected to experience growth at the highest rate, registering a CAGR of 6.6% during the forecast period.
North America accounted for approximately one-half of the global prostate cancer treatment market share in 2018, and is expected to remain dominant throughout the forecast period. This was attributed to the higher adoption of prostate cancer treatment products, large presence of pharmaceutical companies, well developed healthcare infrastructure, and wide availability of prostate cancer treatment drugs. On the other side, Asia-Pacific is expected to experience the highest growth rate during the forecast period majorly due to improvement in healthcare infrastructure, rise in number of hospitals equipped with advanced medical facilities, developing R&D sector, rise in healthcare reforms, and technological advancements in the field of healthcare.
Note: Product cover images may vary from those shown
4 of 5
  • Astellas Pharma Inc.
  • AstraZeneca plc
  • Bayer AG
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche AG
  • Ferring Pharmaceuticals Inc.
  • GlaxoSmithKline Plc
  • Ipsen Pharma
  • Johnson & Johnson
  • Takeda Pharmaceutical Company Ltd.
Note: Product cover images may vary from those shown
5 of 5

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...

Adroll
adroll